Alumis to Participate in Upcoming February Investor Conferences
Rhea-AI Summary
Alumis (Nasdaq: ALMS) will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook: Biotech Summit on February 11-12 in New York with a fireside chat on February 12 at 9:00 AM ET, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26 with a presentation on February 26 at 3:20 PM ET.
Live webcasts will be available on the company’s Investors > Events page, and replay archives will remain on the website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ALMS declined 0.04%, reflecting a mild negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $3.36B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ALMS was down 2.55% while peers were mixed: ERAS up 6.24%, ATXS up 0.8%, PRTA up 1.37%, ITOS up 0.1%, and CRVS down 2.99%. Momentum scanner only flagged LXRX up 5.51%, suggesting a stock-specific setup rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Offering closed | Negative | +7.8% | Closed upsized underwritten offering with 20,297,500 shares at $17.00. |
| Jan 07 | Offering priced | Negative | +10.4% | Priced upsized 17,650,000-share offering at $17.00 per share. |
| Jan 06 | Offering proposed | Negative | +95.3% | Proposed $175.0M common stock offering with 30-day underwriter option. |
| Jan 06 | Phase 3 topline | Positive | +95.3% | Positive Phase 3 envudeucitinib psoriasis data with strong PASI responses. |
| Jan 05 | Data call announced | Neutral | -7.2% | Announced conference call and webcast timing for ONWARD topline data. |
Recent history shows strong positive price reactions to both positive Phase 3 data and follow-on offerings, while a pre-data conference-call announcement saw a negative move.
Over early January 2026, Alumis reported positive Phase 3 ONWARD topline data for envudeucitinib with a 95.31% 24-hour move, followed by a proposed, priced and then closed upsized offering that also saw strong positive reactions of 95.31%, 10.41%, and 7.82%. A prior conference-call announcement on Jan 5, 2026 led to a -7.2% move. Against this backdrop, the current February investor-conference notice fits a pattern of active investor outreach after major clinical and financing milestones.
Regulatory & Risk Context
Alumis has an active Form S-3 shelf registration filed on 2025-07-03, expiring on 2028-07-03. It has been used once, reflected by a 424B5 filing on 2026-01-08 following the recent offering.
Market Pulse Summary
This announcement outlines Alumis’ participation in February investor conferences, including a Guggenheim biotech summit and the Oppenheimer healthcare conference, with specific presentation times and a 90-day webcast archive. Set against recent positive Phase 3 psoriasis data and an upsized January offering, the events extend the company’s investor-outreach effort. Observers may watch for any additional clinical, regulatory, or financing commentary that emerges from these appearances relative to prior disclosures.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:
- Guggenheim Emerging Outlook: Biotech Summit 2026
February 11-12, 2026, New York, NY
Fireside chat: Thursday, February 12, 2026 at 9:00 am ET
- Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 25-26, 2026, Virtual
Presentation: Thursday, February 26, 2026 at 3:20 pm ET
To access the live webcasts please visit the “Events” page of the “Investors" section of the Alumis website. Webcast replays will be archived on the company's website for 90 days.
About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
When will Alumis (ALMS) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?
What time is Alumis (ALMS) scheduled to present at the Oppenheimer Healthcare Life Sciences Conference?
How can investors watch the Alumis (ALMS) webcasts for the February 2026 conferences?
Will Alumis (ALMS) provide replay access after the February 2026 conference presentations?
